throbber
874
`
`FLUORESCENT ANTIBODY RESPONSE IN LASSA, MOBALA, AND IPPY
`STRAINS USING SPECIFIC ANTIBODIES
`
`*Convalescent serum from Lassa fever patient (provided by CDC), at working dilution
`1/32.
`t Mouse immune ascitic fluid against Ippy virus prepared in Bangui (no 272), at working
`dilution= 1/40.
`4:Lassa/Mozambique nucleocapsid specificity, 2093-0004 at working dilution 1/20;
`Lassa/Mozambique nucleocapsid specificity, 2054-0006 at working dilution 1/40; Lassa
`glycoprotein specificity, 2074-0007 at working dilution 1/20; Lassa/Mozambique
`nucleocapsid specificity, 2129-0018 at working dilution 1/20.
`
`Dr Swanepoel (March 16, p 639) has reported that the prototype
`strain of Ippy virus, isolated in 1970, is a member of the Lassa fever
`complex. The "Ippy" strains studied by us and by Swanepoel et al
`seem to differ in that our strain reacted with monoclonal antibody
`2093-0004 while Swaneopoel’s did not (2093-0004 is the same as
`5293-4). These two strains are identified as Ippy viruses by classical
`tests but the use of monoclonal antibodies may now be revealing
`some differences in epitopes.
`Institut Pasteur de Bangui,
`BP923, Bangui, Central African Republic
`Centers for Disease Control,
`Atlanta, Georgia
`
`D. Y. MEUNIER
`
`J. B. MCCORMICK
`
`Institut Pasteur de Bangui
`
`Orstrom; Bangui
`
`M. C. GEORGES
`
`J. P. GONZALEZ
`
`1. Digoutte JP Annual report of Institut Pasteur, Bangui, Central African Republic,
`1970: 59
`2. Kiley MP, Tomori O, Regnery AL, Johnson KM. Characterisation ofthe Arenaviruses
`Lassa and Mozambique. In: Bishop DHL, Compans RW, eds. The replication of
`negative strand viruses. Amsterdam: Elsevier North Holland, 1981: 1-9.
`3. Gonzalez JP, McCormick JB, Saluzzo JF, Georges AJ. An arenavirus isolated from wild
`caught rodents (Praomys sp) in the Central African Republic. Intervirology 1983; 19:
`105-12.
`4. Wulff H, Lange JV. Indirect immunofluorescence for the diagnosis of Lassa fever
`infections. Bull WHO 1975; 52: 429-36.
`5. Johnson KM, Elliott LH, Heymann KL. Preparation of polyvalent viral
`immunofluorescent intercellular antigens and use in human serosurveys. J Clin
`Microbiol 1981; 5: 527-29.
`
`GLYCOSYLATED HAEMOGLOBIN IN
`IRON-DEFICIENCY ANAEMIA
`SIR,-A 1984 Lancet editorial discusses interference with the
`measurement of glycosylated haemoglobin used to evaluate long-
`term control of blood glucose, and cites as an example Brooks and
`colleagues’ report of the increased glycosylation of haemoglobin, as
`measured by a cation-exchange microcolumn method, in association
`with iron-deficiency anaemia.3 However, the ion exchange
`chromatography method yields peaks that are likely to be
`contaminated by non-glycosylated haemoglobin.4 4
`Affinity
`chromatography is thought to be more specific, and this is the
`method we have used in our attempt to confirm Brooks’ findings.
`We selected fourteen patients with iron-deficiency anaemia. Four
`patients were male and ten female, ages ranged from 27 to 89 years
`(mean 54 y), and all were non-diabetic. The mean glycosylated Hb
`(6-9±0-9% SD) was not significantly different from normal
`(7 0--:t I - ° 7070). Only one iron-deficient patient had a value (8 - ° 8°70)
`just above the normal range of 5 - 3-8 - 6%. All patients responded to
`oral iron with significant increases in haematological indices but
`their mean glycosylated haemoglobin values did not change
`(6 - 5-t I - 7%).
`The high levels of HbAI reported with cation-exchange
`chromatography may be due to post-translational modifications of
`haemoglobin other than glycosylation in iron deficiency, the
`
`modified haemoglobin co-eluting with HbAI. Support for this
`suggestion is provided by a study in which raised HbAla+b levels
`but normal or reduced HbA1c levels were reported in association
`with iron deficiency. Such a modification would not influence
`affinity gel procedures which depend on binding between the gel
`and glucose residues on globin chains only.
`We conclude that when affinity gel separation is used iron-
`deficiency anaemia does not produce high glycosylated
`haemoglobin values.
`Department of Pathology,
`Kingston Hospital,
`Galsworthy Road,
`Kingston Upon Thames,
`Surrey KT2 7QB
`
`C. VAN HEYNINGEN
`R. G. DALTON
`
`1. Editorial. Glycosylation and disease. Lancet 1984; ii: 19-20.
`2 Nathan DM, Singer DE, Hurxthal K, et al. The clinical information value of the
`glycosylated hemoglobin assay. N Engl J Med 1984; 310: 341-46.
`3 Brooks AP, Metcalfe J, Day JL, Edwards M. Iron deficiency and glycosylated
`haemoglobin A, Lancet 1980; ii: 141.
`4. Garlick RL, Mazer JS, Higgins PJ, Bunn HF Characterization of glycosylated
`haemoglobins. J Clin Invest 1983; 71: 1062-72
`5. Fairbanks VF, Zimmerman BR. Measurement of glycosylated haemoglobin by affinity
`chromatography Mayo Clin Proc 1983; 58: 770-73.
`6. Hall PM, Cook JGH, Gould BJ. An inexpensive, rapid and precise affinity
`chromatography method for the measurement of glycosylated haemoglobins. Ann
`Clin Biochem 1983; 20: 129-35.
`7. Horton BF, Huisman THJ. Studies on the heterogeneity of haemoglobin. Br J Haemat
`1965; 11: 296-304.
`
`REGRESSION OF METASTATIC VIPOMA WITH
`SOMATOSTATIN ANALOGUE SMS 201-995
`
`SIR,-Vasoactive intestinal polypeptide (VIP) has been implicated
`as the cause of the severe watery diarrhoea of Verner-Morrison
`syndrome and raised blood levels are found in patients with
`bronchogenic carcinoma, phaeochromocytoma, ganglioneuro-
`blastoma, and pancreatic tumours. Early diagnosis and resection of
`a vipoma may be curative, but inoperable or metastatic vipomas are
`difficult to treat. Intravenous somatostatin suppresses VIP
`secretion but its plasma half-life is only 1-1-3-0 0 min.2 SMS
`201-995 is a synthetic octapeptide with a longer half-life which can
`be given by subcutaneous injection; it also suppresses VIP levels.
`We report a case of a metastatic vipoma treated with SMS 201-995
`50 g once daily.
`A 75-year-old woman with a 9 year history of watery diarrhoea
`associated with hypokalaemia and mild hyperglycaemia was found
`to have raised plasma VIP levels. The primary tumour was removed
`
`,""un’n;) o
`
`Fig 1-Neurotensin, VIP and PP levels before and during treatment
`with SMS 201-995.
`Normal ranges: VIP <30 pmol/l; PP <300
`pmol/l; neurotensin <200 pmol I
`ARGENTUM
`Exhibit 1062
`
`000001
`
`

`

`by partial pancreatectomy in October, 1977, but liver secondaries
`could not be resected. In 1981 she was started on tolbutamide for
`diabetes, this treatment being replaced by insulin in March, 1983.
`By June, 1984, she was having watery diarrhoea up to fifteen
`times a day passing 1 - 5-2 litres, had lost weight, and was
`hypokalaemic despite potassium supplementation. Her plasma
`VIP, pancreatic polypeptide (PP), and neurotensin concentration
`were raised; gastrin and glucagon levels were normal.
`SMS 201-995 50 g once daily produced a progressive
`improvement in hormone levels (fig 1) accompanied by a weight
`gain of 5 kg, reduced stool frequency and volume, and correction of
`hypokalaemia. There have been no side-effects, apart from a
`reduced insulin requirement. Computerised axial tomography (CT)
`after 5 months of treatment revealed a reduction in the number, size,
`and contrast enhancement of the liver secondaries (fig 2).
`
`Fig 2-CT scan appearances before (upper) and after (lower) SMS
`201-995 treatment.
`
`Vipomas are often accompanied by increases in neurotensin-like
`immunoreactivity and pancreatic polypeptide levels, as in our
`patient. Her main problem was profound secretory diarrhoea, and,
`though the specific peptide responsible for this diarrhoea is not
`known, VIP remains the most likely candidate.
`There has been considerable interest in the use ofSMS 201-995
`in the treatment of tumours and- diarrhoea, and some success has
`been reported in the treatment ofvipomas, 5-10 including one case of
`regression of liver secondaries and a response without tumour
`regression.9 Our patient has improved considerably on once-daily
`treatment (given at the same time as the insulin by the district nurse)
`with 50 g of SMS 201-995, with improvement of symptoms, CT
`scan appearances, and VIP, PP, and neurotensin levels. The CT
`evidence supports a direct effect of SMS 201-995 on the tumour as
`a mechanism for the clinical and biochemical improvement. This
`patient’s tumour has been successfully controlled with once-daily
`
`875
`
`treatment for 9 months so far. However, the exact place of SMS
`201-995 remains to be defined in the lighl of long-term follow-up of
`its effects and possible complications.
`We thank Dr R. Shentall of Sandoz for the supply of SMS 201-995. The
`pepttde assays were done at the Royal Postgraduate Medical School, London,
`in Prof S. R. Bloom’s department.
`Department of Medicine,
`Queen Elizabeth Hospital,
`Birmingham B15 2TH
`
`D. CLEMENTS
`E. ELIAS
`
`1 Ruskone A, Rene E, Chayvialle JA, et al. Effect of somatostatin on diarrhoea and on
`small intestinal water and electrolyte transport in a patient with pancreatic cholera.
`Dig Dis Sci 1982, 27: 459-66
`2. Sheppard M, Shapiro B, Pimstone B, Kronheim S, Berelowitz M, Gregory M.
`Metabolic clearance and plasma half-disappearance time of exogenous somatostatin
`in man. J Clin Endocrinol Metab 1979; 48: 50-33.
`3 Blackburn AM, Bryant MG, Arian TE, Bloom SR. Pancreatic tumours produce
`neurotensin. J Clin Endocrinol Metab 1981; 51: 820-22.
`4 Long RG, Bryant MG, Mitchell SJ, et al. Clinicopathological study of pancreatic and
`ganglioneuroblastoma tumours secreting vasoactive intestinal polypeptide
`(vipomas). Br Med J 1982; 282: 1767-71.
`5. Von Werder K, Losa M, Muller OA, et al. Treatment of metastasing GRF-producing
`tumour with long-acting somatostatin analogue. Lancet 1984; ii: 282-83
`6. Kraenzlin ME, Ch’ng JC, Wood SM, Bloom SR. Can inhibition of hormone secretion
`be associated with endocrine tumour shrinkage? Lancet 1983; ii: 1501
`7. Kraenzlin ME, Ch’ng JLC, Wood SM, Bloom SR. Remission of symptoms and
`shrinkage of metastasis with long term treatment with somatostatin analogue Gut
`1984; 25: A576
`8. Williams NS, Cooper JC, Axon ATR, King RFGJ, Barker M. Use of a long acting
`somatostatin analogue in controlling life threatening ileostomy diarrhoea. Br Med J
`1984, 289: 1027-28.
`9. Maton PN, O’Dorisio TM, McArthur KE, et al. Effect of long-acting somatostatin
`analogue (SMS 201-995) in a patient with pancreatic cholera. N Engl J Med 1984;
`312: 17-21
`10. Plewe G, Beyer J, Krause U, Neufield M, Del Pozo E. Long-acting and selective
`suppression of growth hormone by somatostatin analogue SMS 201-995 in
`acromegaly. Lancet 1984; ii: 782-84.
`
`RENAL FUNCTION IN DIABETICS
`
`SIR,-Lancet correspondence about renal function in diabetics
`(Jan,5, p 53; Feb 23, p 466) prompted us to review our research. We
`have investigated the prevalence of diabetic nephropathy in a
`general diabetic population (G; n=843) and amongst diabetics
`attending a special eye clinic (R; n = 115). Group G was drawn from
`a well-defined epidemiological population and group R consists of
`patients with serious diabetic retinopathy (maculopathy or
`preproliferative or proliferative changes, confirmed by an
`ophthalmologist). Both groups contained non-insulin-dependent
`and insulin-dependent diabetics.
`Urine samples were tested for proteinuria (’Albustix’) and
`patients were asked to submit a timed overnight urine collection to
`measure albumin excretion rate (AER). However, as the response
`rate for these samples was poor, a sample from a midstream urine
`specimen passed at the clinic was taken and the random urinary
`albumin/creatinine (albumin in mg/l, creatinine in mmol/1) ratio
`(RA/C) measured. A micro-ELISA technique I was used to measure
`urinary albumin and the Jaffe method for urinary creatinine. In our
`laboratory the upper limits of normal are 7’ 5 pg/min for AER and
`1-9 9 for RA/C (mean + 2SD after log transformation in 114 non-
`diabetic controls). Infected urine specimens are excluded.
`As expected, the prevalence of proteinuria was greater in group R
`than in group G (see table). Microalbuminuria was also commoner.
`This is consistent with the similar microangiopathic basis of
`retinopathy and nephropathy.
`Our findings confirm that macroalbuminuria and micro-
`albuminuria are more common in diabetics with serious
`retinopathy. Since, according to our figures, 40% of patients with
`a treatable blinding condition will be missed, there is little case
`for using microalbuminuria to identify these diabetics with
`retinopathy. Also, its use to predict future retinopathy remains
`
`ALBUMINURIA IN TWO DIABETIC POPULATIONS
`
`000002
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket